Overview

GSK706769/KALETRA Drug-drug Interaction Study

Status:
Completed
Trial end date:
2008-11-08
Target enrollment:
Participant gender:
Summary
To compare plasma GSK706769 PK following repeat administration of GSK706769 QD with and without KALETRA (LPV 400 mg/RTV 100mg) q12h
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Lopinavir